To evaluate the efficacy of rituximab as maintenance therapy following remission induction with CHOP chemotherapy. To evaluate the effect of rituximab on immune function. To evaluate the effect of rituximab on HIV viral load. Bidimensionally measurable disease.
All stages are eligible.
All patients must be off colony-stimulating factor therapy at least 24 hours prior to chemotherapy. Creatinine less than 2.0 unless due to lymphoma. KPS greater than 70. At least 18 years of age. Able to give consent.